Abstract | BACKGROUND/AIMS: METHOD: Among 91 incident patients who started CAPD with either biocompatible PD solution (Balance®, Fresenius; LS, n = 48) or conventional PD solution ( CAPD/DPCA®, Fresenius; CS, n = 43), 63 patients, who were followed for 12 months, were enrolled and followed for an additional 12 months. RESULTS: After 24 months of treatment, the glomerular filtration rate (GFR) of the LS group was twofold higher compared to the CS group (33.5 ± 30.7 vs. 16.3 ± 17.9 l/week/1.73 m(2), respectively, p = 0.021). In a subgroup of patients with an initial GFR >2 ml/min/1.73 m(2), the GFR of the LS group was significantly higher than the rate of the CS group after 24 months (43.7 ± 30.5 vs. 18.6 ± 19.0 l/week/1.73 m(2), respectively, p = 0.042). Over a 24-month period, effluent cancer antigen-125 levels were significantly increased in the LS group compared to the CS group, while effluent interleukin-6 levels did not differ between the two groups. The serum tCO(2) levels were consistently higher in the LS group compared to the CS group. CONCLUSIONS: We found that the effect of LS on preserving RRF may be maintained over a 24-month treatment period in CAPD patients, and LS use may have other benefits, such as the correction of metabolic acidosis.
|
Authors | Sejoong Kim, Kook-Hwan Oh, Jieun Oh, Soo Jin Kim, Wookyung Chung, Young Rim Song, Ki Young Na, Yun Kyu Oh, Curie Ahn, Sung Gyun Kim, Kathryn C B Tan |
Journal | American journal of nephrology
(Am J Nephrol)
Vol. 36
Issue 4
Pg. 305-16
( 2012)
ISSN: 1421-9670 [Electronic] Switzerland |
PMID | 23007025
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 S. Karger AG, Basel. |
Chemical References |
- Adipokines
- Biocompatible Materials
- Biomarkers
- Dialysis Solutions
- Glycation End Products, Advanced
|
Topics |
- Acidosis
(metabolism, therapy)
- Adipokines
(metabolism)
- Adult
- Aged
- Biocompatible Materials
(administration & dosage, metabolism)
- Biomarkers
(metabolism)
- Comorbidity
- Dialysis Solutions
(administration & dosage, metabolism)
- Female
- Follow-Up Studies
- Glomerular Filtration Rate
(physiology)
- Glycation End Products, Advanced
(metabolism)
- Humans
- Kidney
(physiology)
- Kidney Failure, Chronic
(mortality, physiopathology, therapy)
- Male
- Middle Aged
- Peritoneal Dialysis, Continuous Ambulatory
(methods)
- Peritoneum
(physiology)
- Peritonitis
(mortality)
- Prospective Studies
- Risk Factors
|